Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

Autor: Hidenori Sasaki, Makoto Wada, Koichi Hirata, Tadashi Ikeda, Toshiaki Saeki, Akifumi Yamamoto, Yoshikazu Kagami, Yutaka Okawa, Naohito Shimoyama, Masayuki Takeda, Toshihiko Nishidate, Yasuhiro Udagawa, Kazuo Tamura, Narikazu Boku, Kenjiro Aogi, Yasuo Shima, Keisuke Aiba, Hirofumi Fujii, Kazuhiko Nakagawa, Kenji Eguchi, Hideki Takeuchi, Kenji Okita, Ryuhei Tanaka, Yusuke Onozawa, Tatsuo Akechi
Rok vydání: 2015
Předmět:
Zdroj: International Journal of Clinical Oncology
ISSN: 1437-7772
1341-9625
DOI: 10.1007/s10147-015-0852-1
Popis: The purpose of this article is to disseminate the standard of antiemetic therapy for Japanese clinical oncologists. On the basis of the Appraisal of Guidelines for Research and Evaluation II instrument, which reflects evidence-based clinical practice guidelines, a working group of the Japanese Society of Clinical Oncology (JSCO) reviewed clinical practice guidelines for antiemesis and performed a systematic review of evidence-based domestic practice guidelines for antiemetic therapy in Japan. In addition, because health-insurance systems in Japan are different from those in other countries, a consensus was reached regarding standard treatments for chemotherapy that induce nausea and vomiting. Current evidence was collected by use of MEDLINE, from materials from meetings of the American Society of Clinical Oncology National Comprehensive Cancer Network, and from European Society of Medical Oncology/Multinational Association of Supportive Care in Cancer guidelines for antiemesis. Initially, 21 clinical questions (CQ) were selected on the basis of CQs from other guidelines. Patients treated with highly emetic agents should receive a serotonin (5-hydroxytryptamine; 5HT3) receptor antagonist, dexamethasone, and a neurokinin 1 receptor antagonist. For patients with moderate emetic risk, 5HT3 receptor antagonists and dexamethasone were recommended, whereas for those receiving chemotherapy with low emetic risk dexamethasone only is recommended. Patients receiving high-emetic-risk radiation therapy should also receive a 5HT3 receptor antagonist. In this paper the 2010 JSCO clinical practice guidelines for antiemesis are presented in English; they reveal high concordance of Japanese medical circumstances with other antiemetic guidelines that are similarly based on evidence.
Databáze: OpenAIRE
Externí odkaz: